Krystal Biotech, Inc.KRYS
NasdaqGS•Healthcare•Biotechnology
Analyze revenue and earnings growth — the core drivers of long-term shareholder returns.
TTM revenue reached $417.30M, growing 25.1% year-over-year. TTM net income stood at $225.03M (81.5% growth). Quarterly EBITDA was $55.21M and operating income was $53.69M. Consistent revenue and earnings growth are the primary drivers of long-term shareholder returns. Analyze KRYS growth trends across revenue, EBITDA, operating income, and net income.
Revenue and earnings growth across quarters